Key Insights

Highlights

Success Rate

97% trial completion (above average)

Published Results

63 trials with published results (32%)

Research Maturity

169 completed trials (86% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

3.1%

6 terminated out of 196 trials

Success Rate

96.6%

+10.1% vs benchmark

Late-Stage Pipeline

49%

97 trials in Phase 3/4

Results Transparency

37%

63 of 169 completed with results

Key Signals

63 with results97% success

Data Visualizations

Phase Distribution

185Total
Not Applicable (23)
P 1 (14)
P 2 (51)
P 3 (63)
P 4 (34)

Trial Status

Completed169
Unknown9
Recruiting7
Terminated6
Active Not Recruiting2
Not Yet Recruiting2

Trial Success Rate

96.6%

Benchmark: 86.5%

Based on 169 completed trials

Clinical Trials (196)

Showing 20 of 20 trials
NCT07055542Not ApplicableRecruiting

Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study

NCT04544774Recruiting

The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy

NCT07398859Phase 2RecruitingPrimary

Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis

NCT07436234Phase 2Not Yet RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis

NCT07052097Phase 2CompletedPrimary

Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis

NCT03369704Phase 3CompletedPrimary

Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients

NCT07291284Phase 3Active Not RecruitingPrimary

Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis

NCT06046391Phase 2CompletedPrimary

Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult

NCT03570957Phase 1CompletedPrimary

A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients

NCT06300203Phase 2RecruitingPrimary

Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis

NCT05692154Phase 3CompletedPrimary

A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis

NCT07091357Phase 2RecruitingPrimary

A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis

NCT07146126Phase 3Not Yet RecruitingPrimary

A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis

NCT06760182Phase 2CompletedPrimary

Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis

NCT04815668Not ApplicableRecruitingPrimary

Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis

NCT06861101Phase 2CompletedPrimary

Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults

NCT06837233Phase 2Active Not RecruitingPrimary

A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis

NCT06846385Phase 2RecruitingPrimary

Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis

NCT05540717Phase 3CompletedPrimary

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

NCT05346718Not ApplicableCompleted

Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis

Scroll to load more

Research Network

Activity Timeline